Editors' (re)View

Welcome to Editors' (re)View, our editors’ weekly takes on things going on in the pharma world that deserve some extra consideration.

Articles

Editor's review: Big Pharma doubles down on manufacturing investments

This week, drug manufacturers — including Amgen, Eli Lilly, Novo Nordisk and Sanofi — announced plans to expand their production footprints in the U.S., Europe and Asia.

Editors' (re)View: J&J's third bankruptcy bid faces DOJ pushback

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of October 21

Editors' (re)View: Warren asks FTC to step in on Novo, Catalent merger

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of October 6

Editors' (re)View: A new era of pharmacological innovation

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of Sept 23

Editors' (re)View: Granules India Limited hit with 483

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of Sept 16

News

Novo obesity drug reduces heart failure-related symptoms

Editors' (re)View: Lilly ventures into the dark genome; China's crackdown on pharma

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Sept 2

Editors' (re)View: Emergent secures mpox vax approval; The DTC push

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 26.

Editors' (re)View: Supply chains and espionage; Emergent sends mpox vaccines to Africa

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 19

Editors' (re)View: Incyte stays busy; A generic IRA perspective

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 11

Editors' (re)View: Roche takes a chance on genomics; Weight loss drugs beyond obesity treatment

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 5

Editors' (re)View: The fate of Lykos’ MDMA treatment; Pfizer gives up on DMD gene therapy

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 28

Editors' (re)View: FDA’s rare disease push; Strides in Batten disease treatment

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 21

Editors' (re)View: Greetings from Portugal; The future of weight loss drugs

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 14

Editors' (re)View: FDA second chances; FTC takes aim at PBMs

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 8

Editors' (re)View: BARDA bucks for MCM; Landmark Alzheimer’s approval

Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 1